Gimv and Edmond de Rothschild Investment Partners have led a Series B equity financing round of €12m in Complix, a biopharmaceutical company focused on the discovery and development of novel therapeutics.
Complix is headquartered in Hasselt, Belgium at life sciences incubator BioVille, and has research facilities in Ghent and in Luxembourg. Since its founding in 2008 Complix has raised a total of €26m in funding. The financing round will be used to develop a first set of therapeutic producrs for treatment of cancer and auto-immune indications, it said.
Patrick Van Beneden, partner at Gimv, said, “We are very excited by the Complix opportunity because it perfectly fits in our Health & Care platform strategy for biotech investments. The company combines high-quality and experienced management with a unique technology platform that has the potential to deliver multiple breakthrough products. These are backed by a strong IP position and a focused business plan that we believe will deliver significant, clear shareholder value within a realistic timeframe. This investment confirms Gimv’s continued interest in this market segment.”
Complix is the sixth joint biotech investment in the current portfolio of Gimv and Biotech Fonds Vlaanderen alongside to Ablynx, Actogenix, Agrosavfe, Multiplicom and Pronota.
Copyright © 2013 AltAssets